Cognition Therapeutics Price Target Increased by H.C. Wainwright

H.C. Wainwright has increased its price target for Cognition Therapeutics (CGTX) to $6 from $5, while keeping a Buy rating on the shares. This adjustment comes after the company announced positive top-line results from the Phase 2 SHIMMER trial of its leading candidate, CT1812, a sigma-2 receptor modulator, in patients with dementia with Lewy bodies. The firm has incorporated the dementia with Lewy bodies indication into its valuation assessment, assigning it a 30% likelihood of approval.